Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, has received new US patent from US Patent and Trademark Office (USPTO) covering the formulation of the company’s radiolabeled dopamine transporter (DAT) receptor ligand, NAV5001, used with SPECT imaging for potential differential diagnosis of Parkinsonian Syndromes and Dementia with Lewy Bodies. The patent (8,574,545) will expire in 2031.

The new US patent, “Labeled Iodinated Tropane Formulation,” extends the scope and longevity of the NAV5001 intellectual property (IP) portfolio. The high concentration formulation protected by this patent may afford greater commercial flexibility and manufacturing efficiency to optimize distribution. Navidea anticipates commencing the NAV5001 phase III clinical programme by year end.

This new patent reinforces the Company’s NAV5001 platform alongside previously issued US Patent 8,084,018, “Methods for Imaging Dopamine Transporter Level,” which covers the acquisition of Dopamine Transporter SPECT images soon after injection of NAV5001, a unique feature and competitive advantage for NAV5001. These patents were issued to Alseres Pharmaceuticals and have been licensed exclusively to Navidea.

Navidea Biopharmaceuticals, Inc. is developing multiple precision diagnostic products and platforms including NAV4694, NAV5001, Manocept and RIGScan, to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making and, ultimately, patient care.